🇺🇸 FDA
Pipeline program

NE-58095 IR

CCT-401

Phase 3 small_molecule completed

Quick answer

NE-58095 IR for Involutional Osteoporosis is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Involutional Osteoporosis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials